Nexalin Technology, Inc. (NXL): Operating Income

Annual figures by period end, from SEC filings.

-$8.39M

Year ended 2025-12-31

-$9.13M

Trailing 12 months to 2026-06-30

2021-12-31 Operating Income (USD) 2025-12-31

Period ended	Operating Income	Change YoY	Source filing
2025-12-31	-$8.39M	n/m	2026-03-25, From 2025-01-01
2024-12-31	-$7.75M	n/m	2026-03-25, From 2024-01-01
2023-12-31	-$5.70M	n/m	2025-09-23, From 2023-01-01
2022-12-31	-$1.83M	n/m	2024-03-27, From 2022-01-01
2021-12-31	-$6.02M	n/a	2023-03-27, From 2021-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Electromedical & Electrotherapeutic Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
Nexalin Technology, Inc. (NXL)	2025-12-31	-$8.39M	n/m
Positron Corp (POSC)	2025-12-31	-$10.50M	n/m
iTonic Holdings Ltd (ITOC)	2025-12-31	-$5.19M	n/m
Guided Therapeutics Inc (GTHP)	2025-12-31	-$2.37M	n/m
Hongchang International Co., Ltd (HCIL)	2024-12-31	-$383.3K	n/m
ADM Tronics Unlimited, Inc. (ADMT)	2026-03-31	-$159.1K	n/m
Neuraxis, Inc (NRXS)	2025-12-31	-$7.83M	n/m
Yubo International Biotech Ltd (YBGJ)	2025-12-31	-$1.19M	n/m
Nuwellis, Inc. (NUWE)	2025-12-31	-$11.11M	n/m

Compare NXL, POSC, ITOC, GTHP side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗